IRX Therapeutics Raises $8 Million to Develop Therapeutic Vaccines for Cancer and Viral Diseases John D. Halpern and George P. Denny III join its Board of Directors IRX Therapeutics Announces Cancer Vaccine Collaboration with Japan's NCRC IRX-2 Immunomodulator Selected for Use in Proof-of-Concept Clinical Trials in Multiple Cancer Indications Neil L. Berinstein, M.D. Joins IRX Team IRX Therapeutics appoints Neil L. Berinstein, M.D. Chief Scientific Officer
